<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00469625</url>
  </required_header>
  <id_info>
    <org_study_id>Z # 13178</org_study_id>
    <nct_id>NCT00469625</nct_id>
  </id_info>
  <brief_title>A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease</brief_title>
  <official_title>A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Winthrop University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Winthrop University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic Nephropathy and other proteinuric renal diseases are the major cause of kidney&#xD;
      disease in the United States. The degree of proteinuria is associated with risk for renal&#xD;
      disease progression and cardiovascular outcomes. Deficiency of 1-25 Vitamin D develops early&#xD;
      in CKD, and is undertreated. Vitamin D may have important effects on factors that drive&#xD;
      proteinuria and renal disease progression in patients with proteinuric renal diseases.&#xD;
      Therefore, Paricalcitol treatment may reduce proteinuria and slow renal deterioration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
        1. To determine the effect of oral paricalcitol on protein excretion in patients with&#xD;
           proteinuric renal diseases&#xD;
&#xD;
        2. To determine the effect of oral paricalcitol on renal disease progression in patients&#xD;
           with proteinuric renal diseases Hypothesis: Oral paricalcitol will reduce protein&#xD;
           excretion in proteinuric kidney disease Study Design: Prospective, randomized, placebo&#xD;
           controlled, double blind, trial of paricalcitol compared to placebo.&#xD;
&#xD;
      Sample Size: 60 patients, 30 in each group Summary of Patient Eligibility Criteria: Subjects&#xD;
      with proteinuric renal disease (&gt;400 mg/24 hours)&#xD;
&#xD;
      Randomization and Dosage: Patients will be randomized to treatment with oral paricalcitol&#xD;
      (initial dose 1 mcg orally per day) compared to placebo Duration : 6 Months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Investigator left the Institution.&#xD;
  </why_stopped>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Proteinuric Renal Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paricalcitol (initial dose 1 mcg orally per day)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Stable chronic kidney disease&#xD;
&#xD;
          2. Urine protein : Creatinine ratio &gt; 0.4&#xD;
&#xD;
          3. Chronic kidney disease stage 2-4 with eGFR 15-90 ml/min&#xD;
&#xD;
          4. PTH (intact) &gt;20 pg/ml and &lt;250 pg/ml&#xD;
&#xD;
          5. Age 18-85&#xD;
&#xD;
          6. If on ACEI/ARB, then dose optimized (BP, K)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Failure to provide informed consent&#xD;
&#xD;
          2. Glomerunephritis requiring active treatment with immunosuppresive therapy&#xD;
&#xD;
          3. Serum phosphorus &gt; 5.2&#xD;
&#xD;
          4. Serum calcium (adjusted for albumin)&gt; 10.0&#xD;
&#xD;
          5. Active malignancy&#xD;
&#xD;
          6. Likelihood of requiring renal replacement therapy within 1 year&#xD;
&#xD;
          7. Uncontrolled hypertension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Winthrop Univ. Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>May 3, 2007</study_first_submitted>
  <study_first_submitted_qc>May 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2007</study_first_posted>
  <last_update_submitted>December 24, 2015</last_update_submitted>
  <last_update_submitted_qc>December 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2015</last_update_posted>
  <responsible_party>
    <name_title>Steven Fishbane, MD</name_title>
    <organization>Winthrop-University Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

